| Product NDC: | 51991-796 |
| Proprietary Name: | Rivastigmine Tartrate |
| Non Proprietary Name: | Rivastigmine Tartrate |
| Active Ingredient(s): | 6 mg/1 & nbsp; Rivastigmine Tartrate |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 51991-796 |
| Labeler Name: | Breckenridge Pharmaceutical, Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA091689 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20120613 |
| Package NDC: | 51991-796-33 |
| Package Description: | 30 CAPSULE in 1 BOTTLE (51991-796-33) |
| NDC Code | 51991-796-33 |
| Proprietary Name | Rivastigmine Tartrate |
| Package Description | 30 CAPSULE in 1 BOTTLE (51991-796-33) |
| Product NDC | 51991-796 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Rivastigmine Tartrate |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20120613 |
| Marketing Category Name | ANDA |
| Labeler Name | Breckenridge Pharmaceutical, Inc |
| Substance Name | RIVASTIGMINE TARTRATE |
| Strength Number | 6 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Cholinesterase Inhibitor [EPC],Cholinesterase Inhibitors [MoA] |